Clinical data on Carrick’s samuraciclib and Syros’s SY-5609 show that this mechanism remains a work in progress.
Cstone/EQRX and Shanghai Junshi/Coherus might have approvable anti-PD-(L)1 projects, but can Keytruda be challenged on price?
At a conference largely focused on big biopharma a few biotech catalysts stand out.
Full data from the trial position the Pharmamar/Jazz small-cell lung cancer drug to remain safely on the US market.
Full data from the Poseidon study confirm the anti-CTLA-4 MAb’s activity; with three chemo combos established, however, will it be enough?
The first of 2021’s eight remaining oncology meetings kicks off next week. Here’s what to look out for.
Bayer’s drug shows a benefit in less severe chronic kidney disease patients in Figaro-DKD.
A 21% reduction in the risk of cardiovascular death or hospitalisation paves the way for Jardiance's approval in heart failure with preserved ejection fraction.
Alector, Cassava and Annovis play up mixed data in dementia, but the markets aren’t buying it.